In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's disease.
Shots:
180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.
Additional programs using anti-TNF soon to…
